Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Innocoll Holdings (INNL) seeking strategic alternatives

  • March 17, 2017

The Management of Innocoll Holdings (INNL) has been investigating and continues to investigate strategic options for the Company to maximise shareholder value.


April 04, 2017: U.S. investment firm Gurnet Point Capital is nearing a deal to acquire Ireland-based specialty drugmaker Innocoll Holdings Plc (INNL), people familiar with the matter said.

April 04, 2017: Gurnet Point L.P., a healthcare investment fund, and Innocoll Holdings plc (INNL), a global pharmaceutical and medical device company, today announced that they have reached an agreement on the terms of a recommended offer. Under the recommended offer, Gurnet Point will acquire Innocoll for $1.75 per share in cash, and up to $4.90 in cash from a contingent value right (CVR), for a total potential per share value of up to $6.65 or up to approximately $209 million in aggregate. The initial cash consideration of $1.75 represents a premium of approximately 120 percent to the closing price per Innocoll Share on March 10, 2017, the last dealing day prior to the date on which the anomalous movement in Innocoll’s shares commenced (and a premium of approximately 28 percent to the closing price per Innocoll Share on March 15, 2017, the day prior to Innocoll initiating the commencement of the offer period).